153 related articles for article (PubMed ID: 25545778)
1. Systematic Review of Health Economic Analyses of Measles and Rubella Immunization Interventions.
Thompson KM; Odahowski CL
Risk Anal; 2016 Jul; 36(7):1297-314. PubMed ID: 25545778
[TBL] [Abstract][Full Text] [Related]
2. Modeling the Transmission of Measles and Rubella to Support Global Management Policy Analyses and Eradication Investment Cases.
Thompson KM; Badizadegan ND
Risk Anal; 2017 Jun; 37(6):1109-1131. PubMed ID: 28561947
[TBL] [Abstract][Full Text] [Related]
3. [Effectiveness, population-level effects, and heath economics of measles and rubella vaccination].
Wichmann O; Ultsch B
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Sep; 56(9):1260-9. PubMed ID: 23990088
[TBL] [Abstract][Full Text] [Related]
4. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
Bae GR; Choe YJ; Go UY; Kim YI; Lee JK
Vaccine; 2013 May; 31(24):2661-6. PubMed ID: 23602654
[TBL] [Abstract][Full Text] [Related]
5. Control of measles and rubella through use of attenuated vaccines.
Meyer HM; Hopps HE; Parkman PD; Ennis FA
Am J Clin Pathol; 1978 Jul; 70(1 Suppl):128-35. PubMed ID: 685885
[TBL] [Abstract][Full Text] [Related]
6. Economic analyses of rubella and rubella vaccines: a global review.
Hinman AR; Irons B; Lewis M; Kandola K
Bull World Health Organ; 2002; 80(4):264-70. PubMed ID: 12075361
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of impact of measles rubella campaign on vaccination coverage and routine immunization services in Bangladesh.
Uddin MJ; Adhikary G; Ali MW; Ahmed S; Shamsuzzaman M; Odell C; Hashiguchi L; Lim SS; Alam N
BMC Infect Dis; 2016 Aug; 16():411. PubMed ID: 27519586
[TBL] [Abstract][Full Text] [Related]
8. Cost-benefit studies of vaccinations in Finland.
Elo O
Dev Biol Stand; 1979; 43():419-28. PubMed ID: 118069
[TBL] [Abstract][Full Text] [Related]
9. The virtual elimination of rubella and mumps from the United States and the use of combined measles, mumps and rubella vaccines (MMR) to eliminate measles.
Bart KJ; Orenstein WA; Hinman AR
Dev Biol Stand; 1986; 65():45-52. PubMed ID: 3104117
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of prevaccination screening of health care workers for immunity to measles, rubella and mumps.
Ferson MJ; Robertson PW; Whybin LR
Med J Aust; 1994 Apr; 160(8):478-82. PubMed ID: 8170422
[TBL] [Abstract][Full Text] [Related]
11. [Economic evaluation on different two-dose-vaccination-strategies related to Measles, Mumps and Rubella Combined Attenuated Live Vaccine].
He HQ; Zhang B; Yan R; Li Q; Fu J; Tang XW; Zhou Y; Deng X; Xie SY
Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Aug; 37(8):1121-6. PubMed ID: 27539345
[TBL] [Abstract][Full Text] [Related]
12. Health economics of rubella: a systematic review to assess the value of rubella vaccination.
Babigumira JB; Morgan I; Levin A
BMC Public Health; 2013 Apr; 13():406. PubMed ID: 23627715
[TBL] [Abstract][Full Text] [Related]
13. Measles, mumps and rubella: control by vaccination.
van Druten JA; de Boo T; Plantinga AD
Dev Biol Stand; 1986; 65():53-63. PubMed ID: 3556777
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of measles-rubella vaccination for mothers in early puerperal phase.
Hisano M; Kato T; Inoue E; Sago H; Yamaguchi K
Vaccine; 2016 Feb; 34(9):1208-14. PubMed ID: 26801065
[TBL] [Abstract][Full Text] [Related]
15. Enabling implementation of the Global Vaccine Action Plan: developing investment cases to achieve targets for measles and rubella prevention.
Thompson KM; Strebel PM; Dabbagh A; Cherian T; Cochi SL
Vaccine; 2013 Apr; 31 Suppl 2():B149-56. PubMed ID: 23598476
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
[TBL] [Abstract][Full Text] [Related]
17. [Hot spot: epidemiology of measles and rubella in Germany and the WHO European region].
Matysiak-Klose D
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Sep; 56(9):1231-7. PubMed ID: 23990084
[TBL] [Abstract][Full Text] [Related]
18. Progress in measles and rubella elimination in Iran.
Esteghamati A; Gouya MM; Zahraei SM; Dadras MN; Rashidi A; Mahoney F
Pediatr Infect Dis J; 2007 Dec; 26(12):1137-41. PubMed ID: 18043452
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of nationwide supplementary immunization in Lao People's Democratic Republic: Population-based seroprevalence survey of anti-measles and anti-rubella IgG in children and adults, mathematical modelling and a stability testing of the vaccine.
Hachiya M; Miyano S; Mori Y; Vynnycky E; Keungsaneth P; Vongphrachanh P; Xeuatvongsa A; Sisouk T; Som-Oulay V; Khamphaphongphane B; Sengkeopaseuth B; Pathammavong C; Phounphenghak K; Kitamura T; Takeda M; Komase K
PLoS One; 2018; 13(3):e0194931. PubMed ID: 29596472
[TBL] [Abstract][Full Text] [Related]
20. Measles and Rubella Global Strategic Plan 2012-2020 midterm review report: Background and summary.
Orenstein WA; Cairns L; Hinman A; Nkowane B; Olivé JM; Reingold AL
Vaccine; 2018 Jan; 36 Suppl 1():A35-A42. PubMed ID: 29307368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
